Skip to main content

How can we help you?

  • 21-06-2013

On 20 June 2013, the European Commission imposed fines on the Danish pharmaceutical company Lundbeck (EUR 93.8 million) and four generic manufacturers (EUR 52.2 million) for 'pay-for-delay' agreements relating to generic versions of citalopram, an antidepressant. A few days earlier, the US Supreme Court held in the FTC v. Actavis case that reverse payment settlement agreements are not per se anticompetitive, but must be analysed on an individual basis under the rule of reason test.

Please read more on this topic in our newsletter.

Cookie notice

We care about your privacy. We only use cookies strictly necessary to ensure the proper functioning of our website. You can find more information on cookies and on how we handle your personal data in our Privacy and Cookie Policy.